TruScreen Group (ASX:TRU, NZE:TRU) said that a July 2024 Saudi Arabia study investigating the TruScreen cervical screening technology's performance versus pap smears in cervical cancer detection was peer reviewed and published by the BMC Women's Health journal, according to bourse filings in Australia and New Zealand on Thursday.
The study tested 507 women and reported that Truscreen demonstrated a high sensitivity of 83.3%, compared to 66.7% from pap smears, and a high specificity of 95%, compared with 98.2% from pap smears, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。